Integrated Molecular Characterization Reveals the Pathogenesis and Therapeutic Strategies of Pulmonary Blastoma

Overview

Journal J Natl Cancer Cent

Specialty Oncology

Date 2025 Mar 5

PMID 40040871

Authors

He Tian

Zhenlin Yang

Junhui Yang

Ying Chen

Lin Li

Tao Fan

Tiejun Liu

Guangyu Bai

Yibo Gao

Jie He

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary blastoma (PB) is a rare subtype of lung cancer. Currently, the underlying pathogenesis mechanisms of PB have not been fully illustrated, and the therapeutic approach for this entity is limited.

Methods: Whole-exome sequencing (WES), RNA sequencing, and DNA methylation profiling are applied to seven PB patients. Multi-omics data of pulmonary sarcomatoid carcinoma (PSC) and pituitary blastoma (PitB) from previous studies are invoked to illuminate the associations among PB and these malignacies.

Results: We portray the genomic alteration spectrum of PB and find that is with the highest alteration rate (86 %). We uncover that alterations, Wnt signaling pathway dysregulation and IGF2 imprinting dysregulation are the potential pathogenesis mechanisms of PB. Moreover, we reveal that the integrated molecular features of PB are distinct from PSC, and the molecular characteristics of PB are more similar to PitB than to PSC. Pancancer analysis show that the tumor mutation burden (TMB) and leukocyte fraction (LF) of PB are low, while some cases are positive for PD-L1 or have CD8-positive focal areas, implying the potential applicability of immunotherapy in selected PB patients.

Conclusion: This study depicts the integrated molecular characteristics of PB and offers novel insights into the pathogenesis and therapeutic strategies of PB.

References

Scholz B, Korn C, Wojtarowicz J, Mogler C, Augustin I, Boutros M . Endothelial RSPO3 Controls Vascular Stability and Pruning through Non-canonical WNT/Ca(2+)/NFAT Signaling. Dev Cell. 2016; 36(1):79-93. DOI: 10.1016/j.devcel.2015.12.015. View

Lindet C, Vanhuyse M, Thebaud E, Robin Y, Penel N . Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide. Acta Oncol. 2010; 50(1):156-7. DOI: 10.3109/0284186X.2010.491087. View

Schultz K, Rednam S, Kamihara J, Doros L, Achatz M, Wasserman J . , and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017; 23(12):e76-e82. DOI: 10.1158/1078-0432.CCR-17-0629. View

Isobe T, Seki M, Yoshida K, Sekiguchi M, Shiozawa Y, Shiraishi Y . Integrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma. Cancer Res. 2017; 78(4):865-876. DOI: 10.1158/0008-5472.CAN-17-2581. View

Hill D, Ivanovich J, Priest J, Gurnett C, Dehner L, Desruisseau D . DICER1 mutations in familial pleuropulmonary blastoma. Science. 2009; 325(5943):965. PMC: 3098036. DOI: 10.1126/science.1174334. View

Reck M, Remon J, Hellmann M . First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022; 40(6):586-597. DOI: 10.1200/JCO.21.01497. View

Bugter J, Fenderico N, Maurice M . Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2020; 21(1):5-21. DOI: 10.1038/s41568-020-00307-z. View

Rim E, Clevers H, Nusse R . The Wnt Pathway: From Signaling Mechanisms to Synthetic Modulators. Annu Rev Biochem. 2022; 91:571-598. DOI: 10.1146/annurev-biochem-040320-103615. View

Nagae G, Yamamoto S, Fujita M, Fujita T, Nonaka A, Umeda T . Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun. 2021; 12(1):5423. PMC: 8450290. DOI: 10.1038/s41467-021-25430-9. View

10.

Foulkes W, Priest J, Duchaine T . DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer. 2014; 14(10):662-72. DOI: 10.1038/nrc3802. View

11.

Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W . Exon 3 mutations of drive tumorigenesis: a review. Oncotarget. 2018; 9(4):5492-5508. PMC: 5797067. DOI: 10.18632/oncotarget.23695. View

12.

Yang Z, Xu J, Li L, Li R, Wang Y, Tian Y . Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun. 2020; 11(1):4878. PMC: 7522294. DOI: 10.1038/s41467-020-18702-3. View

13.

Nakatani Y, Miyagi Y, Takemura T, Oka T, Yokoi T, Takagi M . Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol. 2004; 28(7):921-7. DOI: 10.1097/00000478-200407000-00012. View

14.

de Kock L, Bah I, Wu Y, Xie M, Priest J, Foulkes W . Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung. J Thorac Oncol. 2016; 11(3):e31-3. DOI: 10.1016/j.jtho.2015.09.012. View

15.

Cutler C, Michel R, Yassa M, Langleben A . Pulmonary blastoma: case report of a patient with a 7-year remission and review of chemotherapy experience in the world literature. Cancer. 1998; 82(3):462-7. DOI: 10.1002/(sici)1097-0142(19980201)82:3<462::aid-cncr6>3.0.co;2-r. View

16.

de Kock L, Bah I, Brunet J, Druker H, Astigarraga I, Bosch-Barrera J . Somatic DICER1 mutations in adult-onset pulmonary blastoma. Eur Respir J. 2016; 47(6):1879-82. DOI: 10.1183/13993003.00172-2016. View

17.

de Kock L, Sabbaghian N, Druker H, Weber E, Hamel N, Miller S . Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 2014; 128(4):583-95. PMC: 4381868. DOI: 10.1007/s00401-014-1318-7. View

18.

Meng Z, Chen P, Zang F, Liu Y, Xu X, Su Y . A patient with classic biphasic pulmonary blastoma harboring fusion responds to crizotinib. Onco Targets Ther. 2018; 11:157-161. PMC: 5749379. DOI: 10.2147/OTT.S150001. View

19.

Honda S, Arai Y, Haruta M, Sasaki F, Ohira M, Yamaoka H . Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer. 2008; 99(11):1891-9. PMC: 2600691. DOI: 10.1038/sj.bjc.6604754. View

20.

Lococo F, Torricelli F, Rossi G, Alifano M, Damotte D, Rapicetta C . Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. Lung Cancer. 2017; 113:93-101. DOI: 10.1016/j.lungcan.2017.09.009. View